Modelling drug-related morbidity in Sweden using an expert panel of pharmacists'

International Journal of Clinical Pharmacy

Volumn 34, Issue 4, 2012, Pages 538-546

  Gyllensten, Hanna ^a   Hakkarainen, Katja M ^a   Jönsson, Anna K ^b,c   Sundell, Karolina Andersson ^a   Hägg, Staffan ^b,c   Rehnberg, Clas ^d   Carlsten, Anders ^a,e  

^a NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Department of Clinical Immunology and Transfusion Medicine   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

Adverse effects; Cost of illness; Decision trees; Delphi technique; Drug therapy; Drug related morbidity; Preventability; Sweden

Indexed keywords

ADVERSE DRUG REACTION; AMBULATORY CARE; ARTICLE; CLINICAL PRACTICE; COST OF ILLNESS; DECISION TREE; DRUG DEPENDENCE; DRUG INTOXICATION; DRUG RELATED MORBIDITY; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; MORBIDITY; OBSERVATIONAL STUDY; OUTPATIENT CARE; PHARMACIST; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SWEDEN; UNITED STATES;

DECISION TREES; DRUG TOXICITY; EXPERT TESTIMONY; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; MORBIDITY; PHARMACISTS; SWEDEN;

EID: 84867397248     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9641-3     Document Type: Article

References (31)

1. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64(5):566-76.
2. Jönsson AK, Spigset O, Tjäderborn M, Druid H, Hägg S. Fatal drug poisonings in a Swedish general population. BMC Clin Pharmacol. 2009;9:7.
3. Leendertse AJ, Visser D, Egberts AC, van den Bemt PM. The relationship between study characteristics and the prevalence of medication-related hospitalizations: a literature review and novel analysis. Drug Saf. 2010;33(3):233-44.
4. Kanjanarat P, Winterstein AG, Johns TE, Hatton PC, Segal R. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm. 2003;60(17):1750-9.
5. Thomsen LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41(9):1411-26.
6. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24(2):46-54.
7. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008; 42(7):1017-25.
8. Rodríguez-Monguió R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics. 2003;21(9):623-50.
9. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155(18): 1949-56.
10. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41(2):192-9.
11. Stark RG, John J, Leidl R. Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach. BMC Health Serv Res. 2011;11:9.
12. Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med. 1990;228(2):83-90.
13. Nysam. Nyckeltal 2009 rapport Va°rdkonsumtion. Swedish: The Association; 2010. p. 1-47.
14. Statistics Sweden. Sweden's population nearing 9.5 million. [Updated 18 Feb 2011; cited 31 Jan 2012]. Available from: http://www.scb.se/Pages/ PressRelease-308294.aspx.
15. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997; 277(4):307-11.
16. Evans RS, Classen DC, Stevens LE, Pestotnik SL, Gardner RM, Lloyd JF, et al. Using a hospital information system to assess the effects of adverse drug events. Proc Annu Symp Comput Appl Med Care. 1993;161-5.
17. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol. 1998;45(3):301-8.
18. Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring - cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf. 1997;6(Suppl 3):S79-90.
19. Vargas E, Terleira A, Hernando F, Perez E, Cordon C, Moreno A, et al. Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med. 2003;31(3):694-8.
20. Swedish Association of Local Authorities and Regions. Statistik om hälso-och sjukva°rd samt regional utveckling 2010. Swedish: The Association; 2011. p. 1-216.
21. Swedish Association of Local Authorities and Regions. Jämförelse av kostnader och verksamhet pa° sjukhuskliniker 2009. Swedish: The Association; 2010. p. 1-38.
22. Swedish Association of Local Authorities and Regions. Löne-och prisförändring för landsting och KPI. [Updated 27 May 2009; cited 31 Jan 2012]. Available from: http://www.skl.se/vi-arbetar-med/ekonomi/budget- och-planering/prisindex/landstingsprisindex.Swedish.
23. Sveriges Riksbank. A°rsgenomsnitt valutakurser (ackumulerat). [Updated 1 Jan 2011; cited 31 Jan 2012]. Available from: http://www.riksbank.se/ sv/Rantor-och-valutakurser/Arsgenomsnitt-valutakurser/.Swedish.
24. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother. 2002; 36(7-8):1238-48.
25. Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379-407.
26. Henriksson F, Jönsson B. Diabetes: the cost of illness in Sweden. J Intern Med. 1998;244(6):461-8.
27. Statistics Sweden. Svenska hälsoräkenskaper 2001-2010. [Updated 30 Mar 2012; cited 20 Apr 2012]. Available from: http://www.scb.se/Pages/ ProductTables-231546.aspx.Swedish.
28. Yousuf MI. Using experts' opinions through Delphi techniques. Pract Assess Res Eval. 2007;12(4):1-8.
29. Brown BB. Delphi process: a methodology used for the elicitation of opinions of experts. RAND Corp. 1968;P-3925:1-14.
30. Karnon J, Brown J. Selecting a decision model for economic evaluation: a case study and review. Health Care Manag Sci. 1998;1(2):133-40.
31. Rice DP. Estimating the cost of illness. Am J Public Health Nations Health. 1967;57(3):424-40.